As part of an effort to heighten awareness of its work in research, treatment and care — as well as to raise funds — the Muscular Dystrophy Association (MDA) has proclaimed September MDA National Muscular Dystrophy Awareness Month. The launch dovetails with World Duchenne Awareness Day, observed annually…
News
Online forums have markedly altered how patients, caregivers, and healthcare professionals communicate and connect. Even when miles apart, individuals can establish supportive relationships, share experiences and information, and sometimes simply vent. Bionews Services, a leading online health, science and research publication company, has been rolling out its…
Vamorolone (VBP15), an experimental treatment for Duchenne muscular dystrophy (DMD) developed by ReveraGen Biopharma, improves muscle function of DMD patients in a dose-dependent manner, data from a Phase 2a extension study shows. The Phase 2b VISION-DMD (VBP15-004) trial (NCT03439670) for vamorolone is currently recruiting participants in…
Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest. Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s co-founder,…
Many people are inspired by a son or brother with Duchenne muscular dystrophy (DMD). When it comes to Danielle Edwards, she’s literally made the disease her career. Edwards, 26, is the community engagement manager at the Jett Foundation, a Massachusetts charity that helps families deal with the emotional and…
Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies in…
Most parents of children with Duchenne muscular dystrophy and adults with this disease — who took part in an interview study arranged and owned by Parent Project Muscular Dystrophy (PPMD) — expressed “cautious optimism” about gene therapy as a potential DMD treatment, weighing potential benefits against risks and disease…
The nonprofit CureDuchenne has chosen veteran advocacy leader Erin Frey to become its first director of Duchenne muscular dystrophy (DMD) advancement efforts. In her official capacity as senior director of advocacy, Frey is charged with establishing relationships that promote CureDuchenne’s outreach, and connect Duchenne families and other…
The U.S Food and Drug Administration (FDA) has rejected Sarepta Therapeutic’s application seeking accelerated approval of golodirsen (SRP-4053) for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. Golodirsen (SRP-4053) was placed under priority review by the FDA in February 2019. The FDA’s complete response…
Fulcrum Therapeutics announced it has launched ReDUX4, a Phase 2b clinical trial designed to assess the safety and efficacy of losmapimod, an investigational treatment for facioscapulohumeral muscular dystrophy (FSHD) in patients with a genetically confirmed diagnosis of FSHD. The Phase 2b ReDUX4 trial (NCT04003974) is recruiting…
Recent Posts
- I found a new FSHD life hack to respond to my worsening leg weakness
- Gene therapy restores key protein in models of rare muscular dystrophy
- Being good at handling a medical scare doesn’t make this DMD mom happy
- DM1 therapy shows promise over year of testing, trial data suggest
- Pursuing meaningful work while living with Duchenne muscular dystrophy